How to license a technology from ICMR: the EoI process, eligibility and royalty terms
How to license a technology from ICMR in India: Expression of Interest calls on Patent Mitra, who can apply, documents, the 2% royalty and key license terms.
Part of the guide Licensing technology from Indian institutions: the complete guide for companies
ICMR licenses its diagnostics, devices and other biomedical technologies through Expression of Interest (EoI) calls. A company registers on ICMR's Medical Innovation Patent Mitra portal, submits the e-EoI with its documents and a short business plan, is screened against pre-qualification criteria, and if shortlisted signs a licence or development agreement. Under ICMR's 2024 collaboration guidelines, licensing is non-exclusive by default with a 2% royalty on net sales, and the product must be commercialised within two years.
The Indian Council of Medical Research (ICMR) and its institutes develop diagnostics, devices, assays and other biomedical technologies, and many of them are offered to Indian companies for licensing. For a diagnostics maker, a device company or a pharma MSME, an ICMR licence can be a faster route to a validated product than starting from zero.
The process is more structured than most university deals. ICMR works through public Expression of Interest (EoI) calls with fixed eligibility rules, a published royalty and standard agreements. This guide walks through each step, based on ICMR's own guidelines and recent EoI calls. It is practical guidance, not legal advice, and the EoI for your technology has the final word.
The short answer
ICMR licenses technologies after publishing an EoI. You register on ICMR's Medical Innovation Patent Mitra portal (patentmitra.icmr.org.in), submit the e-EoI with signed formats, certificates and a business plan of up to five pages, and ICMR screens and shortlists applicants. Shortlisted companies sign an agreement. Under the 2024 Guidelines for Technology Development Collaboration, licences are non-exclusive by default, the royalty for licensing is 2% of net sales, and you must commercialise within two years.
Which rules apply
Two ICMR documents matter:
- Technology Transfer and Revenue Sharing Guidelines (July 2021). These set royalty in a range of 1% to 5% of net sales, linked to the technology readiness level (TRL) at licensing, with a technology transfer fee fixed case by case.
- Guidelines for Technology Development Collaboration (2024). These cover material transfer, joint development, licensing and validation, and set flat royalty rates by model. The 2026 EoI calls we reviewed cite these guidelines.
Read the EoI and draft agreement for your technology to see which terms apply. Where this guide quotes a number, it says which document it comes from.
Step 1: Find the technology
ICMR advertises technologies through its website, publications and partner agencies, and issues EoI calls one technology at a time. The calls are published on the ICMR website and run through Patent Mitra.
Each EoI is detailed. Two recent examples:
- A lymphatic filariasis immunoassay (May 2026), developed at ICMR-NIVCR, Puducherry. The EoI states TRL 5 (third-party validated) and reports 92.5% sensitivity and 100% specificity in external validation. The submission window was nine days.
- A microcontroller-based mosquito feeder device (August 2026), also from ICMR-NIVCR. The EoI states TRL 4 (validated in-house) and gives the Indian patent application number. The window was three weeks.
Notice how short these windows are. If biomedical technology matters to your business, someone on your team should check ICMR calls every week. You can also check the patent status of any ICMR technology on IP India's public search before you apply, as our patent due diligence checklist explains.
Step 2: Check you are eligible
ICMR's guidelines and EoIs set pre-qualification criteria. The common ones:
- Indian ownership. A company incorporated under the Companies Act 2013 with at least 51% of shares held by Indian citizens, or an LLP where at least half the partners are Indian citizens. Foreign or foreign-equity entities need the Competent Authority's approval.
- Tax registration (GST or PAN).
- Experience. At least three years of manufacturing or R&D experience, with similar products on the market. This can be waived for startups, which must show a DPIIT certificate.
- Financial health. For commercial firms, no overall loss over the past three years.
- Clean record. Not blacklisted, and no convictions in the past three years.
- Facilities. A manufacturing unit in India, GMP or ISO certification for manufacturing, GLP for R&D, and a working laboratory.
- Capacity. A stated minimum production quantity per week, set in each EoI.
EoIs say relaxations apply to MSMEs and startups under Government of India guidelines. If you are a startup without a factory, read the relaxation wording closely and ask the contact named in the EoI before you apply.
Step 3: Prepare and submit the e-EoI
Recent EoIs ask for:
- Six formats: the EoI declaration, an authorisation letter, undertakings on blacklisting and non-conviction, a laboratory facility undertaking and a production capacity undertaking.
- Supporting documents: incorporation papers, GST or PAN, any CDSCO or DCGI licence for existing products, audited accounts or a CA certificate, proof of office and factory, GMP, GLP or ISO certificates and an MSME certificate if you have one.
- A business concept note of up to five pages, covering R&D, clinical studies where relevant, production and marketing, with timelines.
Every page must be stamped and signed by the authorised signatory. You register on Patent Mitra, fill in the company and representative details and submit the e-EoI online. Late, unsigned or incomplete applications may be rejected.
The concept note is where most applicants lose ground. ICMR shortlists on your R&D plan, facilities and capabilities, so show how you will take this specific technology to market: the regulatory route, the validation still needed, the production plan and the sales channel.
Licensing an ICMR technology, step by step
Step 4: Screening, shortlisting and due diligence
ICMR's process has three stages: screening against the pre-qualification criteria with document checks, shortlisting on the R&D plan, facilities and capabilities, and then contacting qualified companies to sign an MoA, MoU or agreement. ICMR may ask for clarifications and may amend, cancel or reissue an EoI.
Before you see confidential data, you sign a non-disclosure agreement. Use this window well. Check the patent's claims and status, the validation data, any regulatory filings and who else is likely to hold a non-exclusive licence. ICMR licenses technology "as is where is", without warranty, so the risk of the technology not working at your scale sits with you.
Step 5: The licence terms
These are the terms most companies ask about. The figures are from the 2024 guidelines unless stated.
Royalty. For licensing, 2% of net sales. Other models have their own rates: 1% for material transfer for product development, 2% for joint development and commercialisation, and 1% for validation by ICMR. The royalty has a sunset of 10 years from commercialisation. Waivers are possible only in exceptional cases.
Exclusivity. Non-exclusive by default, to maximise public access. Exclusive licences need review by the Licensing and Collaborations Committee and approval by the Competent Authority. Expect competitors to be able to license the same technology.
Payment and reporting. Royalties are paid half-yearly: for the period to 31 March, by the last working day of April, and for the period to 30 September, by the last working day of October. Late payment carries 12% simple interest a year. Three consecutive missed payments lead to automatic termination after a 30-day notice to remedy.
Commercialisation deadline. You must commercialise within two years of licensing. If you do not, ICMR can exercise march-in rights. Extensions can be requested in writing with reasons.
IP in improvements. Background IP stays with whoever created it. Foreground IP from licensing or co-development is jointly owned by ICMR and the company. Improvements that claim priority from, or are obvious modifications of, the original invention are jointly owned too.
Termination. ICMR gives one month's notice to remedy a breach. You must give at least three months' notice to end the licence. After termination you may use the know-how for up to 30 days to finish orders already in production.
Disputes. Thirty days of consultation, then arbitration seated in New Delhi.
The 2021 guidelines add obligations you may also see in older agreements, such as a 10% share of any sub-licensing income for ICMR, royalty statements certified by a chartered accountant, ICMR's right to audit, and registration of patent-derived products on the GeM portal at a discounted price for government buyers. Our guide to technology licence agreement clauses explains how to read each of these.
ICMR licence terms: 2021 and 2024 guidelines
What a licence really costs you
The headline royalty is low, but it is not the whole cost. Budget for:
- Validation you still need. A TRL 4 device validated in-house is far from a product. Plan for engineering, scale-up and testing.
- Regulatory approvals. Diagnostics and devices need CDSCO licensing before sale, and that takes time and money.
- Handholding costs. Under the 2021 guidelines, ICMR scientists support the know-how transfer and the licensee pays their travel and stay at actuals.
- Any upfront fee. The 2024 guidelines do not specify one, and the 2026 EoIs we reviewed did not mention one, but the 2021 guidelines provide for a transfer fee set by valuation. Ask before you commit.
A fair way to compare options is to put the ICMR route next to building in-house or licensing elsewhere, as in our guide to build, buy or license decisions.
Common mistakes
- Missing the window. Some EoIs close within days. Watch the calls every week.
- Treating TRL as product readiness. Read the stated TRL and plan the work between it and launch.
- A generic business plan. Five pages specific to the technology beat a company brochure.
- Assuming exclusivity. Plan for others to hold the same licence, and compete on execution.
- Ignoring the two-year clock. If you cannot launch in two years, agree milestones and an extension route in writing.
Looking beyond one institution
ICMR is one strong source of biomedical technology among many. Before you commit to a single EoI, it helps to see what else exists for the same problem. Zernyx Hub, India's technology licensing marketplace for businesses, has mapped patents from universities across India, with AI-generated business insight on each, including commercial applications. You can use Zernyx Hub to shortlist options across institutions before you prepare an EoI.
FAQ
How do I find ICMR technologies available for licensing?
ICMR publishes EoI calls on its website and runs them through the Medical Innovation Patent Mitra portal. It also promotes technologies through its publications and partner agencies. Check the calls regularly, because windows can be short.
What documents does an ICMR EoI need?
Recent EoIs ask for six signed formats, incorporation papers, GST or PAN, regulatory licences for existing products, audited accounts or a CA certificate, proof of office and factory, quality certificates and a business concept note of up to five pages.
What royalty does ICMR charge?
Under the 2024 guidelines, 2% of net sales for licensing, with a 10-year sunset from commercialisation. The 2021 guidelines used a 1% to 5% range linked to TRL. Check your EoI and agreement.
How long do I have to launch the product?
Two years from licensing, under both sets of guidelines. If you do not commercialise in time, ICMR can exercise march-in rights, so agree realistic milestones before you sign.